Observes a CAR-T cell therapy in adults with returning or resistant B-cell leukemia
Observes how inaticabtagene autoleucel works in adults with relapsed or refractory leukemia.
Plain-language title generated from the registry record
Registry title: Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
Key facts
- Where
- Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, and Zhengzhou, ChinaSee the 10 sites
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
- Peking University Third HospitalBeijing, ChinaTaking people
- West China School of Medicine/West China Hospital of Sichuan UniversityChengdu, ChinaTaking people
- Zhujiang Hospital of Southern Medical UniversityGuangzhou, ChinaTaking people
- Qilu Hospital of Shandong UniversityJinan, ChinaTaking people
- Tongji Hospital of Tongji UniversityShanghai, ChinaTaking people
- Institute of Hematology & Blood Diseases HospitalTianjin, ChinaTaking people
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
- The affiliated hospital of xuzhou medical universityXuzhou, ChinaTaking people
- Henan Cancer Hospital,Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Juventas Cell Therapy Ltd.
- Trial code
- NCT06450067
- Record updated
- 19 September 2024
- Original description
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.Read full original descriptionShow less
To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Inclusion: Age ≥ 18 years; Diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia; Patients deemed eligible for receiving commercial Inaticabtagene Autoleucel injection treatment as determined by the investigator; Patients voluntarily participate in this study and sign an informed consent form. For patients lacking full legal capacity, informed consent must be obtained from their legal guardian.
Exclusion: None.